According to a recent investigation, the small-molecule inhibitors FB23 and FB23-2 targeting FTO significantly suppress the proliferation of AML cell flux and primary LSCs in Xeon-transplanted mice by directly reducing m6A demethylase activity of FTO in target mRNA including MYC, CEBPA, RARA and ASB2214. Here, MYC is linked to acute myeloid leukemia.